Impaired autophagy contributes to muscle atrophy in glycogen storage disease type II patients

Anna Chiara Nascimbeni, Marina Fanin, Eva Masiero, Corrado Angelini, Marco Sandri

Research output: Contribution to journalArticle

Abstract

The autophagy-lysosome system is essential for muscle cell homeostasis and its dysfunction has been linked to muscle disorders that are typically distinguished by massive autophagic buildup. Among them, glycogen storage disease type II (GSDII) is characterized by the presence of large glycogen-filled lysosomes in the skeletal muscle, due to a defect in the lysosomal enzyme acid α-glucosidase (GAA). The accumulation of autophagosomes is believed to be detrimental for myofiber function. However, the role of autophagy in the pathogenesis of GSDII is still unclear. To address this issue we monitored autophagy in muscle biopsies and myotubes of early and late-onset GSDII patients at different time points of disease progression. Moreover we also analyzed muscles from patients treated with enzyme replacement therapy (ERT). Our data suggest that autophagy is a protective mechanism that is required for myofiber survival in late-onset forms of GSDII. Importantly, our findings suggest that a normal autophagy flux is important for a correct maturation of GAA and for the uptake of recombinant human GAA. In conclusion, autophagy failure plays an important role in GSDII disease progression, and the development of new drugs to restore the autophagic flux should be considered to improve ERT efficacy.

Original languageEnglish
Pages (from-to)1697-1700
Number of pages4
JournalAutophagy
Volume8
Issue number11
DOIs
Publication statusPublished - Nov 2012

Fingerprint

Glycogen Storage Disease Type II
Muscular Atrophy
Autophagy
Enzyme Replacement Therapy
Lysosomes
Disease Progression
Glucosidases
Muscles
Skeletal Muscle Fibers
Muscular Diseases
Glycogen
Muscle Cells
Skeletal Muscle
Homeostasis
Biopsy
Acids
Survival
Enzymes
Pharmaceutical Preparations

Keywords

  • ATROGIN1
  • Atrophy
  • Autophagy
  • Glycogen storage disease type II
  • MURF-1
  • Muscle wasting
  • Pompe disease

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology

Cite this

Nascimbeni, A. C., Fanin, M., Masiero, E., Angelini, C., & Sandri, M. (2012). Impaired autophagy contributes to muscle atrophy in glycogen storage disease type II patients. Autophagy, 8(11), 1697-1700. https://doi.org/10.4161/auto.21691

Impaired autophagy contributes to muscle atrophy in glycogen storage disease type II patients. / Nascimbeni, Anna Chiara; Fanin, Marina; Masiero, Eva; Angelini, Corrado; Sandri, Marco.

In: Autophagy, Vol. 8, No. 11, 11.2012, p. 1697-1700.

Research output: Contribution to journalArticle

Nascimbeni, AC, Fanin, M, Masiero, E, Angelini, C & Sandri, M 2012, 'Impaired autophagy contributes to muscle atrophy in glycogen storage disease type II patients', Autophagy, vol. 8, no. 11, pp. 1697-1700. https://doi.org/10.4161/auto.21691
Nascimbeni, Anna Chiara ; Fanin, Marina ; Masiero, Eva ; Angelini, Corrado ; Sandri, Marco. / Impaired autophagy contributes to muscle atrophy in glycogen storage disease type II patients. In: Autophagy. 2012 ; Vol. 8, No. 11. pp. 1697-1700.
@article{860b2d7416aa4923b6914ee55f3c580c,
title = "Impaired autophagy contributes to muscle atrophy in glycogen storage disease type II patients",
abstract = "The autophagy-lysosome system is essential for muscle cell homeostasis and its dysfunction has been linked to muscle disorders that are typically distinguished by massive autophagic buildup. Among them, glycogen storage disease type II (GSDII) is characterized by the presence of large glycogen-filled lysosomes in the skeletal muscle, due to a defect in the lysosomal enzyme acid α-glucosidase (GAA). The accumulation of autophagosomes is believed to be detrimental for myofiber function. However, the role of autophagy in the pathogenesis of GSDII is still unclear. To address this issue we monitored autophagy in muscle biopsies and myotubes of early and late-onset GSDII patients at different time points of disease progression. Moreover we also analyzed muscles from patients treated with enzyme replacement therapy (ERT). Our data suggest that autophagy is a protective mechanism that is required for myofiber survival in late-onset forms of GSDII. Importantly, our findings suggest that a normal autophagy flux is important for a correct maturation of GAA and for the uptake of recombinant human GAA. In conclusion, autophagy failure plays an important role in GSDII disease progression, and the development of new drugs to restore the autophagic flux should be considered to improve ERT efficacy.",
keywords = "ATROGIN1, Atrophy, Autophagy, Glycogen storage disease type II, MURF-1, Muscle wasting, Pompe disease",
author = "Nascimbeni, {Anna Chiara} and Marina Fanin and Eva Masiero and Corrado Angelini and Marco Sandri",
year = "2012",
month = "11",
doi = "10.4161/auto.21691",
language = "English",
volume = "8",
pages = "1697--1700",
journal = "Autophagy",
issn = "1554-8627",
publisher = "Taylor and Francis Inc.",
number = "11",

}

TY - JOUR

T1 - Impaired autophagy contributes to muscle atrophy in glycogen storage disease type II patients

AU - Nascimbeni, Anna Chiara

AU - Fanin, Marina

AU - Masiero, Eva

AU - Angelini, Corrado

AU - Sandri, Marco

PY - 2012/11

Y1 - 2012/11

N2 - The autophagy-lysosome system is essential for muscle cell homeostasis and its dysfunction has been linked to muscle disorders that are typically distinguished by massive autophagic buildup. Among them, glycogen storage disease type II (GSDII) is characterized by the presence of large glycogen-filled lysosomes in the skeletal muscle, due to a defect in the lysosomal enzyme acid α-glucosidase (GAA). The accumulation of autophagosomes is believed to be detrimental for myofiber function. However, the role of autophagy in the pathogenesis of GSDII is still unclear. To address this issue we monitored autophagy in muscle biopsies and myotubes of early and late-onset GSDII patients at different time points of disease progression. Moreover we also analyzed muscles from patients treated with enzyme replacement therapy (ERT). Our data suggest that autophagy is a protective mechanism that is required for myofiber survival in late-onset forms of GSDII. Importantly, our findings suggest that a normal autophagy flux is important for a correct maturation of GAA and for the uptake of recombinant human GAA. In conclusion, autophagy failure plays an important role in GSDII disease progression, and the development of new drugs to restore the autophagic flux should be considered to improve ERT efficacy.

AB - The autophagy-lysosome system is essential for muscle cell homeostasis and its dysfunction has been linked to muscle disorders that are typically distinguished by massive autophagic buildup. Among them, glycogen storage disease type II (GSDII) is characterized by the presence of large glycogen-filled lysosomes in the skeletal muscle, due to a defect in the lysosomal enzyme acid α-glucosidase (GAA). The accumulation of autophagosomes is believed to be detrimental for myofiber function. However, the role of autophagy in the pathogenesis of GSDII is still unclear. To address this issue we monitored autophagy in muscle biopsies and myotubes of early and late-onset GSDII patients at different time points of disease progression. Moreover we also analyzed muscles from patients treated with enzyme replacement therapy (ERT). Our data suggest that autophagy is a protective mechanism that is required for myofiber survival in late-onset forms of GSDII. Importantly, our findings suggest that a normal autophagy flux is important for a correct maturation of GAA and for the uptake of recombinant human GAA. In conclusion, autophagy failure plays an important role in GSDII disease progression, and the development of new drugs to restore the autophagic flux should be considered to improve ERT efficacy.

KW - ATROGIN1

KW - Atrophy

KW - Autophagy

KW - Glycogen storage disease type II

KW - MURF-1

KW - Muscle wasting

KW - Pompe disease

UR - http://www.scopus.com/inward/record.url?scp=84869439058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869439058&partnerID=8YFLogxK

U2 - 10.4161/auto.21691

DO - 10.4161/auto.21691

M3 - Article

C2 - 22940840

AN - SCOPUS:84869439058

VL - 8

SP - 1697

EP - 1700

JO - Autophagy

JF - Autophagy

SN - 1554-8627

IS - 11

ER -